Chef Bobby Geetha Launches Bold New Book Showcasing the Future of Indian Fine Dining
Chef Bobby Geetha
LEEDS, United Kingdom, May 01, 2025 (GLOBE NEWSWIRE) -- Acclaimed chef, entrepreneur, and hospitality consultant Bobby Geetha is proud to announce the launch of his latest cookbook and culinary business guide.
Fine Dining Indian At Home is a bold step toward making Indian fine dining accessible, modern, and globally influential. The new title marks his sixth book and blends signature recipes with practical insights for chefs, restaurateurs, and ambitious home cooks alike.
Born in Kerala, India, and now recognised internationally for his innovative take on Indian cuisine, Chef Bobby's culinary journey has taken him from the traditional kitchens of his hometown to Michelin-starred restaurants across Europe. His newest book is a culmination of decades of experience that fuse time-honoured Indian flavours with global culinary techniques.
'This book isn't just about recipes – it's about revolutionising how the world sees Indian cuisine,' said Chef Bobby. 'From home cooks to head chefs, I want people to feel empowered to explore India's culinary depth through a fine dining lens.'
Chef Bobby's career began with a formal education in hospitality in Kerala, before earning a management certificate from Cornell University. He went on to train with world-renowned establishments such as Le Manoir aux Quat'Saisons, Dinner by Heston Blumenthal, The Fat Duck, and Noma. In the UK, his leadership roles spanned hotels like Sofitel London and Novotel Liverpool, and his work on menus has shaped restaurants such as Flora Indica, Fleur Café, and Vermillion.
Bobby's rise to culinary prominence includes reaching the quarter-finals on BBC's MasterChef: The Professionals, competing in the Great British Menu, becoming a semi-finalist in the Craft Guild of Chefs' National Chef of the Year and earning the title of UAE's Best Indian Chef (2019) alongside receiving the Hospitality Chef Excellence Gold Award (2018).
His business ventures include multiple UK-based restaurants and cafés, such as the Kerala Canteen, inspired by the traditional toddy shops of southern India, and the franchisable Nesso Café concept. He is also the founder of Fine Dining Indian, a digital platform and media hub that champions modern Indian cuisine globally.
Beyond the plate, Bobby is deeply involved in consultancy work for hospitality groups and ghost kitchens, advising on everything from kitchen planning and menu design to FMCG product development.
His latest book reflects that unique duality: artistry and strategy. With Fine Dining Indian At Home, Chef Bobby offers not only a blueprint for refined Indian cooking but also a guide for anyone looking to transform passion into profession.
Fine Dining Indian At Home is available now via chefbobbygeetha.com.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/16d1e57f-bd40-408b-8f21-5f08c30898ce
CONTACT: CONTACT Bobby Geetha COMPANY: Fine Dining Indian Ltd EMAIL: bobbygeetha@finediningindian.com WEB: https://chefbobbygeetha.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
The News Forum Announces Launch of Western Canada Bureau, Taps Veteran Journalist Hal Roberts as Lead Anchor
ST. CATHARINES, Ontario, June 06, 2025 (GLOBE NEWSWIRE) -- The News Forum is proud to announce the official launch of its new Western Canada Bureau, marking a significant expansion of its national news coverage. This strategic move is further strengthened by the appointment of seasoned broadcast journalist Hal Roberts as the lead anchor for the new Calgary-based operations. With three decades of experience in the broadcast industry, Hal Roberts brings a wealth of knowledge and a distinguished career to The News Forum. His extensive background includes covering provincial and federal politics as a parliamentary reporter in Ottawa, leading national business programs, and anchoring newscasts across Canada. 'We are absolutely thrilled to be expanding The News Forum's footprint with new studios in Western Canada,' said Tore Stautland, CEO of The News Forum. 'Bringing on an anchor of Hal Roberts' caliber is a testament to our commitment to delivering high-quality, comprehensive news to all Canadians. His deep understanding of the region and his impressive journalistic integrity will be invaluable as we build out our Western coverage.' Roberts' career highlights include his impactful reporting on the 2014 Ottawa terrorist attack, his role as a national correspondent for business programs on BNN, Global TV, and CHCH-TV, and his significant contributions as an anchor and producer in major Canadian markets. He is also an award-winning journalist, having received a Crystal Communicator award for his work on a national news/current affairs program and an award for a TV show on human trafficking. 'I am incredibly excited to join The News Forum and lead the charge in establishing our Western Canada Bureau,' said Hal Roberts. 'This is a fantastic opportunity to contribute to a growing news organization dedicated to insightful and balanced reporting, in times where regional perspectives are of increased importance. I look forward to connecting with viewers across the West and bringing their stories to a national audience.' This expansion into Western Canada is a key step in The News Forum's broader growth strategy. 'Our vision extends beyond the West; we are also actively working towards establishing a strong presence in Montreal,' added Stautland. 'This national expansion underscores our dedication to providing diverse perspectives and robust news coverage from coast to coast to coast.' The News Forum's Western Canada Bureau, under Hal Roberts' leadership, will significantly enhance the network's ability to cover regional stories with depth and accuracy, further solidifying its position as a vital source of Canadian news and current affairs. About The News Forum: The News Forum is a Canadian news and current affairs television network dedicated to providing in-depth analysis and diverse perspectives on important issues facing Canadians. With a commitment to journalistic integrity, The News Forum aims to foster informed discussion and understanding. The News Forum is a national Canadian news broadcaster available through most television distributors – see local listings. TNF is a subscriber to the Canadian Press/AP along with other significant sources of breaking news from across Canada and around the world. Media ContactDanielle KlammerCMO, The News Additional Information: Website: Daily News Website: Twitter:
Associated Press
35 minutes ago
- Associated Press
Free eBook Offers Expert Tips on Creating Sustainable Kitchens and Baths
Lake City, Colo., June 06, 2025 (GLOBE NEWSWIRE) -- As homeowners seek smarter, healthier, and greener living spaces, Green Builder Media is offering a powerful new resource to help industry professionals and consumers alike make the most of their kitchen and bath upgrades. 'Sustainable Kitchens and Baths: Updating the Most Used Spaces in Your Home for Smarter, Healthier, Greener Living' is a free downloadable eBook packed with practical strategies to reduce carbon emissions, optimize water use, increase energy efficiency, and enhance indoor air quality. Download the book here . From new construction to thoughtful retrofits, the eBook offers inspiration for builders, architects, designers, and homeowners who want their kitchens and baths to be both beautiful and climate-resilient. 'Whether it's embracing induction cooking or choosing cabinetry with low-emissions finishes, these high-use spaces present a huge opportunity for impact,' says Green Builder Media Associate Editor Michele Lerner. According to Green Builder Media's COGNITION Smart Data, nearly 50% of homeowners already use energy-efficient appliances, and more than 25% are interested in adopting induction cooking. A growing number are also exploring leak detection, greywater systems, and hot water recycling as part of a comprehensive water management approach. Inside the eBook: How builders and manufacturers are using recycled materials to create stunning designs The benefits of induction cooking and other cutting-edge appliances Tips for choosing healthy, low-VOC cabinets and finishes How smart water management can save money and protect your home High-performance remodeling strategies that increase comfort, efficiency, and value Download your free copy today and start transforming your kitchen and bath into spaces that truly reflect the future of sustainable living. About Green Builder Media Green Builder Media is North America's leading media company focused on green building and sustainable living content. With a comprehensive suite of content marketing, digital, social, and print media options, high-profile demonstration projects, market intelligence, data services, and live events, Green Builder Media offers a blend of visionary and practical information covering a broad spectrum of topics, including decarbonization, electrification, smart home technologies, energy efficiency, intelligent water, indoor air quality, resilient housing, renewables, and clean transportation. Attachment Get Your Free Copy of Sustainable Kitchens and Baths Cati O'Keefe Green Builder Media 513-532-0185 [email protected]
Associated Press
35 minutes ago
- Associated Press
Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
NEEDHAM, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Maha Radhakrishnan, M.D., to the Company's Board of Directors (Board) effective June 4, 2025. 'We are delighted to welcome Maha as a new member of Candel's Board,' said Paul Peter Tak, M.D., Ph.D., FMedSci, President and Chief Executive Officer of Candel. 'Her extensive industry experience will be extremely valuable as Candel advances its late-stage oncology programs toward potential approval and commercial development, with the aim of providing benefit to patients with significant unmet need.' Dr. Radhakrishnan brings significant experience in product development and commercialization that will be particularly valuable as Candel prepares for its Biologics License Application (BLA) submission for CAN-2409 in intermediate-to-high-risk prostate cancer, anticipated in Q4 2026. 'I am honored to join the Board at this pivotal moment as Candel advances its innovative immunotherapy candidates across multiple cancer indications,' said Dr. Radhakrishnan. 'Candel's multimodal approach has the potential to address significant unmet needs in cancers that have historically been difficult to treat with conventional immunotherapies.' Dr. Radhakrishnan has over 20 years of experience advancing large strategic portfolios across various therapeutic areas through product development and commercialization within major biotechnology and pharmaceutical companies. Since August 2024, Dr. Radhakrishnan has served as an Executive Partner at Sofinnova Investments, a venture capital firm focused on life sciences, where she leads diligence across clinical-ready assets in multiple therapeutic areas and provides expertise to portfolio companies in product development and commercialization. Previously, Dr. Radhakrishnan served as Group Senior Vice President and Chief Medical Officer at Biogen Inc. Earlier in her career, she was Senior Vice President and Global Head of Medical, Primary Care Business Unit at Sanofi S.A. Dr. Radhakrishnan has also held leadership roles at Bioverativ, Inc., Bristol-Myers Squibb Company, UnitedHealth Group, Inc., and Cephalon, Inc. She received her M.D. with honors from the People's Friendship University in Moscow, Russia. 'Maha's expertise will be invaluable as we look forward to her contributions while we prepare to submit our Biologics License Application for CAN-2409 in intermediate-to-high-risk prostate cancer, anticipated in Q4 2026,' said Paul B. Manning, Chairman of Candel's Board. About Candel Therapeutics Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform. The Company recently completed successful phase 2a clinical trials of CAN-2409 in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal phase 3 clinical trial of CAN-2409 in localized prostate cancer, conducted under a Special Protocol Assessment (SPA) agreed with the U.S. Food and Drug Administration (FDA). CAN-2409 plus prodrug (valacyclovir) has been granted Fast Track Designation by the FDA for the treatment of PDAC, stage III/IV NSCLC in patients who are resistant to first line PD-(L)1 inhibitor therapy and who do not have activating molecular driver mutations or have progressed on directed molecular therapy and localized primary prostate cancer. The FDA also granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CAN-2409 for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease and Orphan Drug Designation to CAN-2409 for the treatment of PDAC. CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma (rHGG). Initial results were published in Nature and CAN-3110 received Fast Track Designation and Orphan Drug Designation from the FDA. Finally, Candel's enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. For more information about Candel, visit Forward-Looking Statements This press release includes certain disclosures that contain 'forward-looking statements,' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs; expectations regarding the submission of the Biologics License Application for CAN-2409 in intermediate-to-high-risk localized prostate cancer; and expectations regarding the therapeutic benefit of the Company's platforms. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company's programs; that final data from the Company's preclinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company's ability to efficiently discover and develop product candidates; the Company's ability to obtain and maintain regulatory approval of product candidates; the Company's ability to maintain its intellectual property; the implementation of the Company's business model, including strategic plans for the Company's business and product candidates; and other risks identified in the Company's filings with the U.S. Securities and Exchange Commission (SEC), including the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, each as filed with the SEC and any subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Investor Contact: Theodore Jenkins VP, Investor Relations and Business Development Candel Therapeutics, Inc. [email protected] Media Contact: Ben Shannon ICR Healthcare [email protected]
